Le Lézard
Classified in: Ebola virus, Health
Subject: ACC

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT OCTOBER 2022


GOTHENBURG, Sweden, Nov. 3, 2022 /PRNewswire/ -- Zinzino group revenue increased with a total of 22%, compared with the previous year.

The revenue in October for Zinzino's sales markets increased by 22% and amounted to SEK 125.4 (102.4) million. Faun Pharma's external sales increased by 12% and amounted to SEK 4.8 (4.3) million. Overall, the Group increased revenues by 22% to SEK 130.2 (106.7) million compared with the previous year.

Accumulated revenue for January ? October 2022 increased by 6% to SEK 1144.0 (1076.1) million.

Revenues were distributed as follows:

                                   

                                   

Regions, mSEK

                                   

22-Oct

                                   

21-Oct

                                   

Change

                                   

YTD 2022

                                   

YTD 2021

                                   

Change

                                               

                                   

The Nordics

 

27.8

 

29.2

 

-5 %

 

263.5

 

300.4

 

-12 %

 

                                   

Central Europe

 

27.3

 

18.1

 

51 %

 

223.7

 

180.6

 

24 %

 

                                   

East Europe

 

29.8

 

24.3

 

23 %

 

267.6

 

262.3

 

2 %

 

                                   

South & West Europe

 

15.8

 

11.5

 

37 %

 

129.9

 

114.4

 

14 %

 

                                   

The Baltics

 

6.7

 

6.1

 

10 %

 

59.3

 

58.3

 

2 %

 

                                   

North America

 

11.0

 

4.4

 

150 %

 

63.1

 

40.5

 

56 %

 

                                   

Asia-Pacific

 

5.9

 

8.8

 

-33 %

 

63.5

 

68.1

 

-7 %

 

                                   

Africa

 

1.1

 

0.0


 

7.3

 

0.0


                                   

Zinzino

 

125.4

 

102.4

 

22 %

 

1077.9

 

1024.6

 

5 %

 

                                   

Faun Pharma

 

4.8

 

4.3

 

12 %

 

66.1

 

51.5

 

28 %

 

                                   

Zinzino Group

 

130.2

 

106.7

 

22 %

 

1144.0

 

1076.1

 

6 %

 

Countries in regions:

-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlansds, Slovenia, Spain, United Kingdom, Belgium, Ireland
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa

For more information:
Dag Bergheim Pettersen
CEO Zinzino
+47 (0) 932 25 700,
zinzino.com

Pictures for publication free of charge:
[email protected]

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: [email protected]

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 09:00 the 3rd of November 2022.

The following files are available for download:

https://mb.cision.com/Main/10976/3660370/1647946.pdf

2210 Pressrelease Salesreport EN

 


These press releases may also interest you

9 mai 2024
TCI Group is proud to be participating in Phase 1 of the Alliance for Water Stewardship (AWS) Impact Accelerator. Together we are working in Shanghai Jinshan with AWS Members and five other facilities to expand our knowledge, skills and networks to...

9 mai 2024
A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National...

9 mai 2024
Celltrion USA announced today that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to HUMIRA ® (adalimumab), is now available at a low wholesale acquisition cost (WAC). Adalimumab-aaty will be...

9 mai 2024
Rakuten Medical, Inc., a global...

9 mai 2024
Healthcare technology company RXNT, a leading developer of ambulatory clinical and practice management software, announced its successful transition to the Relay Exchange clearinghouse via Change Healthcare on May 9th, 2024. This...

9 mai 2024
Center for Lyme Action (CLA) and Generation Lyme are pleased to announce a new Community Partnership to leverage each nonprofit organization's distinct resources to support current and future Lyme disease advocates. This collaboration marks a...



News published on and distributed by: